🔗 Share this article Users Stopping Slimming Jabs Regain Pounds Far More Rapidly Compared to Those on Conventional Diets Weight management involves long-term strategies. A recent study reveals that people who discontinue popular GLP-1 drugs like Mounjaro or Wegovy tend to recover reduced body mass far faster than those who end traditional lifestyle plans. Published data in a major medical journal points out that while obese individuals frequently drop a large proportion of their total mass while on the medication, the mass is regained at an estimated rate of 0.8 kg per month once they quit. "Users buying these medications must be informed of the potential of rapid weight regain when the therapy is stopped," stated researcher Dr. Susan Jebb. Such speed of recovery implies a reversion to pre-treatment weight within about 18 months. Analyzing Therapies The analysis, which looked at 37 of trials involving over 9,000 of participants, contrasted the effects of GLP-1 agonists with other pills. The team emphasize that individuals who lose weight through diet and exercise usually experience a less rapid weight regain—perhaps 0.1 kg a month—post-intervention. Explaining the Rapid Rebound Doctors suggest the mechanism of the jabs is key to understanding the amplified regain. These medications mimic a natural hormone called GLP-1, which controls feelings of fullness. "Artificially providing the hormone levels far above than the body's typical production could lead to the system to generate a reduced amount of its own natural hormone, and could reduce responsiveness to its effects," explained Dr. Adam Collins, a dietetics researcher. "Discontinuation of this GLP-1 'fix' means appetite is no longer kept in check, making overeating far more likely." A Lifelong Condition? Health authorities recommend the jabs for people with weight-linked medical conditions, accompanied by recommended diet and exercise modifications. A number of clinicians argue that, due to the likelihood of relapse, the therapy should be considered long-term. This view is echoed by pharmaceutical companies, who state that the findings "emphasize the chronic nature of excess weight," comparing it to managing diseases like diabetes. Patient Testimonies Individuals who have stopped the medication explain a sudden resurgence of appetite. "It was like a switch flipping and you become starving," described a patient. The struggle is worsened if patients have not adopted sustainable dietary or behavioural changes during therapy. Growing Use Survey data indicate that millions of adults in the UK have tried these injections in the past year, with interest continuing to grow. Use is greater among females compared to males. The 40s and 50s demographic shows the greatest level of interest. A large proportion obtain the drugs through private prescriptions rather than public health services. Ultimately, experts emphasize that while these medications are effective agents for weight loss, they are not a standalone cure and maintained weight loss hinges on combined lifestyle changes.
Weight management involves long-term strategies. A recent study reveals that people who discontinue popular GLP-1 drugs like Mounjaro or Wegovy tend to recover reduced body mass far faster than those who end traditional lifestyle plans. Published data in a major medical journal points out that while obese individuals frequently drop a large proportion of their total mass while on the medication, the mass is regained at an estimated rate of 0.8 kg per month once they quit. "Users buying these medications must be informed of the potential of rapid weight regain when the therapy is stopped," stated researcher Dr. Susan Jebb. Such speed of recovery implies a reversion to pre-treatment weight within about 18 months. Analyzing Therapies The analysis, which looked at 37 of trials involving over 9,000 of participants, contrasted the effects of GLP-1 agonists with other pills. The team emphasize that individuals who lose weight through diet and exercise usually experience a less rapid weight regain—perhaps 0.1 kg a month—post-intervention. Explaining the Rapid Rebound Doctors suggest the mechanism of the jabs is key to understanding the amplified regain. These medications mimic a natural hormone called GLP-1, which controls feelings of fullness. "Artificially providing the hormone levels far above than the body's typical production could lead to the system to generate a reduced amount of its own natural hormone, and could reduce responsiveness to its effects," explained Dr. Adam Collins, a dietetics researcher. "Discontinuation of this GLP-1 'fix' means appetite is no longer kept in check, making overeating far more likely." A Lifelong Condition? Health authorities recommend the jabs for people with weight-linked medical conditions, accompanied by recommended diet and exercise modifications. A number of clinicians argue that, due to the likelihood of relapse, the therapy should be considered long-term. This view is echoed by pharmaceutical companies, who state that the findings "emphasize the chronic nature of excess weight," comparing it to managing diseases like diabetes. Patient Testimonies Individuals who have stopped the medication explain a sudden resurgence of appetite. "It was like a switch flipping and you become starving," described a patient. The struggle is worsened if patients have not adopted sustainable dietary or behavioural changes during therapy. Growing Use Survey data indicate that millions of adults in the UK have tried these injections in the past year, with interest continuing to grow. Use is greater among females compared to males. The 40s and 50s demographic shows the greatest level of interest. A large proportion obtain the drugs through private prescriptions rather than public health services. Ultimately, experts emphasize that while these medications are effective agents for weight loss, they are not a standalone cure and maintained weight loss hinges on combined lifestyle changes.